Cost?effectiveness of Anti?CD19 chimeric antigen receptor T?Cell therapy in pediatric relapsed/refractory B?cell acute lymphoblastic leukemia. A societal view

Frederick Thielen; A van Dongen-Leunis; AMM Arons; JR Ladestein; PR Hoogerbrugge

doi:10.1111/ejh.13427

Cost?effectiveness of Anti?CD19 chimeric antigen receptor T?Cell therapy in pediatric relapsed/refractory B?cell acute lymphoblastic leukemia. A societal view

Frederick Thielen, A van Dongen-Leunis, AMM Arons, JR Ladestein, PR Hoogerbrugge

Health Technology Assessment (HTA)

Research output: Contribution to journal › Article › Academic › peer-review

34 Citations (Scopus)

20 Downloads (Pure)

Original language	English
Journal	European Journal of Haematology
Volume	105
Issue number	2
DOIs	https://doi.org/10.1111/ejh.13427
Publication status	Published - 2020

Access to Document

10.1111/ejh.13427

Repub_126668_O-A.pdfFinal published version, 973 KB

http://hdl.handle.net/1765/126668

Cite this

@article{de370d4cbc8b486abab1f6b7692bc1e3,

title = "Cost?effectiveness of Anti?CD19 chimeric antigen receptor T?Cell therapy in pediatric relapsed/refractory B?cell acute lymphoblastic leukemia. A societal view",

author = "Frederick Thielen and {van Dongen-Leunis}, A and AMM Arons and JR Ladestein and PR Hoogerbrugge",

year = "2020",

doi = "10.1111/ejh.13427",

language = "English",

volume = "105",

journal = "European Journal of Haematology",

issn = "0902-4441",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "2",

}

TY - JOUR

T1 - Cost?effectiveness of Anti?CD19 chimeric antigen receptor T?Cell therapy in pediatric relapsed/refractory B?cell acute lymphoblastic leukemia. A societal view

AU - Thielen, Frederick

AU - van Dongen-Leunis, A

AU - Arons, AMM

AU - Ladestein, JR

AU - Hoogerbrugge, PR

PY - 2020

Y1 - 2020

UR - https://onlinelibrary.wiley.com/doi/full/10.1111/ejh.13427

U2 - 10.1111/ejh.13427

DO - 10.1111/ejh.13427

M3 - Article

C2 - 32289184

SN - 0902-4441

VL - 105

JO - European Journal of Haematology

JF - European Journal of Haematology

IS - 2

ER -

Cost?effectiveness of Anti?CD19 chimeric antigen receptor T?Cell therapy in pediatric relapsed/refractory B?cell acute lymphoblastic leukemia. A societal view

Access to Document

Other files and links

Cite this